Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front‐line hypomethylating agents and venetoclax: A retrospective Italian study
British Journal of Haematology · 2026-08 · 209 (2) · 799-803
DOI: 10.1111/bjh.70587 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 28.05.2026. Verfasst von Ilaria Tanasi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Bone Marrow Transplant Unit, Section of Biomedicine of Innovation, Department of Engineering for Innovative Medicine, University of Ve…. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
genetically defined sAML had responses and outcomes closer to dnAML. This observation is consistent with recent molecular data suggesting that myelodysplasia-related spliceo-some mutations, historically viewed as strongly adverse in chemotherapy-treated AML, may not exert the same negative impact in patients treated with HMA-VEN. 8–10 Overall, our findings suggest that, in the venetoclax era, sAML is not a biologically uniform entity and that patients with a documented antecedent myeloid disorder may derive less benefit from this treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology and Bone Marrow Transplant Unit, Section of Biomedicine of Innovation, Department of Engineering for Innovative Medicine, University of Verona, Verona, Italy.
- UCO Ematologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.
- Hematology Unit, Azienda Ospedale-Università and University of Padova, Padua, Italy.
- Department of Hematology, San Bortolo Hospital, Vicenza, Italy.
- Hematology Unit, Azienda ULSS3 Serenissima, Ospedale dell'Angelo, Venice, Italy.
- Division of Hematology and Bone Marrow Transplantation, Department of Medical Area, University of Udine, Udine, Italy.
ORCID-Profile: Ilaria Tanasi, Edoardo Tamellini, Elena Marchetti, Davide Facchinelli, Giulia Battaglia, Alessandra Sperotto, Michele Gottardi, Mauro Krampera, Mario Tiribelli
Zitieren
APA
Tanasi, I., Tamellini, E., Marchetti, E., De Bellis, E., Ancora, C., Angotzi, F., Facchinelli, D., Capraro, F., Battaglia, G., Sperotto, A., Gottardi, M., Leoncin, M., Krampera, M., Tiribelli, M., & Gurrieri, C. (2026). Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front‐line hypomethylating agents and venetoclax: A retrospective Italian study. British Journal of Haematology, 209(2), 799-803. https://doi.org/10.1111/bjh.70587
Vancouver
Tanasi I, Tamellini E, Marchetti E, De Bellis E, Ancora C, Angotzi F, et al. Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front‐line hypomethylating agents and venetoclax: A retrospective Italian study. British Journal of Haematology. 2026;209(2):799-803. doi:10.1111/bjh.70587
BibTeX
@article{Tanasi2026,
author = {Tanasi, Ilaria and Tamellini, Edoardo and Marchetti, Elena and De Bellis, Eleonora and Ancora, Cristina and Angotzi, Francesco and Facchinelli, Davide and Capraro, Francesca and Battaglia, Giulia and Sperotto, Alessandra and Gottardi, Michele and Leoncin, Matteo and Krampera, Mauro and Tiribelli, Mario and Gurrieri, Carmela},
title = {Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front‐line hypomethylating agents and venetoclax: A retrospective Italian study},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {2},
pages = {799--803},
doi = {10.1111/bjh.70587}
}
EUVIMED